Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children

Pfizer and BioNTech have submitted an application to the US Food and Drug Administration (FDA) for the emergency use of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a booster dose for children aged six months to four years.